Literature DB >> 32016714

Response to Comment on: "Stratifying Therapeutic Enoxaparin Dose in Morbidly Obese Patients by BMI Class: A Retrospective Cohort Study".

Young R Lee1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32016714     DOI： 10.1007/s40261-020-00890-x

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN： 1173-2563            Impact factor:   2.859


× No keyword cloud information.
  6 in total

1.  Comment On: "Stratifying Therapeutic Enoxaparin Dose in Morbidly Obese Patients by BMI Class: A Retrospective Cohort Study".

Authors:  Nameer van Oosterom; Karl Winckel; Michael Barras
Journal:  Clin Drug Investig       Date:  2020-03       Impact factor: 2.859

Review 2.  Anticoagulating obese patients in the modern era.

Authors:  Jignesh P Patel; Lara N Roberts; Roopen Arya
Journal:  Br J Haematol       Date:  2011-08-16       Impact factor: 6.998

3.  Development of a dosing strategy for enoxaparin in obese patients.

Authors:  Bruce Green; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

Review 4.  Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings.

Authors:  Edith A Nutescu; Sarah A Spinler; Ann Wittkowsky; William E Dager
Journal:  Ann Pharmacother       Date:  2009-05-19       Impact factor: 3.154

Review 5.  Effect of obesity on the pharmacokinetics of drugs in humans.

Authors:  Michael J Hanley; Darrell R Abernethy; David J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

6.  Stratifying Therapeutic Enoxaparin Dose in Morbidly Obese Patients by BMI Class: A Retrospective Cohort Study.

Authors:  Young R Lee; Peter J Palmere; Caitlin E Burton; Taylor M Benavides
Journal:  Clin Drug Investig       Date:  2020-01       Impact factor: 2.859
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.